Skip to main content

Advertisement

SpringerLink
Log in

Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Due to the possible risk of infusion reactions of rituximab (RTX), a slow infusion rate (total infusion time, 255 min) is suggested for rheumatological use. However, especially in oncology field, accelerated infusion of RTX is reported to be well tolerated and safe. The aim of our study was to evaluate whether accelerated infusion rates of RTX would similarly be safe and tolerable in rheumatoid arthritis (RA) patients and other off-label rheumatological indications. All patients treated with RTX for RA and other autoimmune diseases between May 2011 and January 2012 were recruited to the study. Each treatment course consisted of two RTX 1,000 mg infusions, 2 weeks apart. Total time of the infusion for the first cycle was 255 min. Second and subsequent infusions were administered over 120 min as follows: 0–30 min, 100 mg; 30–60 min, 200 mg; 60–90 min, 300 mg; and 90–120 min, 400 mg. The Clinical Trials Classification of Adverse Events (CTCAE) version 4.3 was used to categorise side effects. The study population comprised 68 patients [F/M, 59:9; mean age, 52.4 (10.6) years]: 60 with RA, 4 with systemic lupus erythematosus (SLE), 1 with non-Hodgkin’s lymphoma with SLE and 3 with vasculitis. A total of 77 fast infusions were administered. Eleven patients (16.2 %) had taken a fast infusion at the first course. A total of nine patients experienced at least one AE. Seven patients had a reaction on the first infusion (infusion-related reaction (IRR)), two patients on the second infusion and one patient on both infusions. When graded from 1 to 5 according to CTCAE v. 4.3, grade 1 IRRs were observed in a total of seven patients and grade 2 IRR in three patients. In this study of fast infusions, adverse events after RTX were mostly mild and seem to be well tolerated. Faster rituximab infusion times seem to be safe and might be incorporated into routine practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, De la Serna Rodriguez A, Díaz-López C, Sanmartí R, Nolla JM (2011) Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 29(6):991–997

    PubMed  Google Scholar 

  2. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45

    Article  PubMed  CAS  Google Scholar 

  3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253–259

    Article  PubMed  CAS  Google Scholar 

  4. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P (2010) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J 128(5):309–310

    PubMed  Google Scholar 

  5. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheumatism 63(12):3692–3701

    Article  PubMed  CAS  Google Scholar 

  6. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18(17):3135–3143

    PubMed  CAS  Google Scholar 

  7. van Vollenhoven RF, Emery P 3rd, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558–567

    Google Scholar 

  8. Tuthill M, Crook T, Corbet T, King J, Webb A (2009) Rapid infusion of rituximab over 60 min. Eur J Haematol 82(4):322–325

    Article  PubMed  CAS  Google Scholar 

  9. Al Zahrani A, Ibrahim N, Al Eid A (2009) Rapid infusion rituximab changing practice for patient care. J Oncol Pharm Pract 15(3):183–186

    Article  PubMed  Google Scholar 

  10. Provencio M, Cerdeira S, Bonilla F, Sánchez A, España P (2006) Rapid-infusion rituximab in lymphoma treatment. Ann Oncol 17(6):1027–1028

    Article  PubMed  CAS  Google Scholar 

  11. Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, Alvarez-Larrán A, Besses C (2006) Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 77(4):338–340

    Article  PubMed  CAS  Google Scholar 

  12. Atmar J (2010) Review of the safety and feasibility of rapid infusion of rituximab. J Oncol Pract 6(2):91–93

    Article  PubMed  Google Scholar 

  13. Chiang J, Chan A, Shih V, Hee SW, Tao M, Lim ST (2010) A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. Int J Hematol 91(5):826–830

    Article  PubMed  CAS  Google Scholar 

  14. Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, Searle B, Souliere S, Spinelli JJ, Sutherland J, Connors JM (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109(10):4171–4173

    Article  PubMed  CAS  Google Scholar 

  15. Larsen JL, Jacobsen S (2012) Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. Rheumatol Int. doi:10.1007/s00296-011-2208-0

  16. Faraawi R, Roth K (2010) Experience with accelerated rituximab infusion for rheumatoid arthritis in a single community practice. Ann Rheum Dis 69(Suppl3):383

    Google Scholar 

  17. Larsen JL, Jacobsen S (2010) Rapid-infusion with rituximab-short term safety in systemic autoimmune disaese. Ann Rheum Dis 69(Suppl3):731

    Google Scholar 

  18. Bukh G, Larsen S, Rasmussen SS, Hansen MS (2011) Very fast infusion-rate of rituximab for rheumatoid arthritis is well tolerated and safe. Ann Rheum Dis 69(Suppl3):507

    Google Scholar 

  19. Bukh G, Larsen S, Rasmussen SS, Hansen MS (2006) Accelerated infusion-rate of rituximab for rheumatoid arthritis is well tolerated and safe. Rituximab. Full Prescribing Information

  20. Rituximab. Full prescribing information (2006), http://www.ema.europa.eu/. Accessed July 2006

  21. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522

    Article  PubMed  Google Scholar 

  22. Prevoo ML, Van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB et al (1995) Modified disease activity scores that include twenty-eight-joint counts:development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  PubMed  CAS  Google Scholar 

  23. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J et al (2011) Updated consessus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909–920

    Article  PubMed  CAS  Google Scholar 

  24. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31(6):456–473

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. School of Medicine, Deparment of Rheumatology, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey

    Meryem Can, Fatma Alibaz-Öner, Sibel Yılmaz-Öner, Pamir Atagündüz, Nevsun İnanç & Haner Direskeneli

Authors
  1. Meryem Can
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatma Alibaz-Öner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sibel Yılmaz-Öner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pamir Atagündüz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nevsun İnanç
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haner Direskeneli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meryem Can.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Can, M., Alibaz-Öner, F., Yılmaz-Öner, S. et al. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience. Clin Rheumatol 32, 87–90 (2013). https://doi.org/10.1007/s10067-012-2094-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2094-1

Keywords

Search

Navigation